Literature DB >> 31858461

Screening of Media Supplements for High-Performance Perfusion Cultures by Design of Experiment.

Patrick Mayrhofer1, Renate Kunert2.   

Abstract

Perfusion is considered as the preferable unit operation mode for fully integrated continuous bioprocessing. However, the inherent complex process control, long process development times, and lack of suitable scale-down models for high-throughput screening are reasons why perfusion processes are still not routinely applied in cell culture technology. Advantages of perfusion are maintenance of a consistent cellular environment, a constant high-quality product flow, enhanced volumetric bioreactor productivity, and small lab footprint. Here, we provide guidelines for screening different proprietary but commercially available HyClone™ Cell Boost™ supplements in a Design of Experiment (DoE) approach to spike the HyClone™ CDM4NS0 basal media for enhanced product titers in small-scale TubeSpin models. These surrogate semi-perfusion cultures were successfully realized by a daily complete media exchange routine resulting in high viable cell densities for extended time periods at minimal media consumption. This technique was leveraged to define the potential of different perfusion media formulations.

Keywords:  DoE; Mammalian cell culture; Perfusion culture; Process development; Response surface methodologies; Scale-down model; Small-scale bioreactor

Year:  2020        PMID: 31858461     DOI: 10.1007/978-1-0716-0191-4_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells.

Authors:  Patrick Mayrhofer; Monika Hunjadi; Renate Kunert
Journal:  Front Bioeng Biotechnol       Date:  2021-12-17

2.  Model predictive control for steady-state performance in integrated continuous bioprocesses.

Authors:  Magdalena Pappenreiter; Sebastian Döbele; Gerald Striedner; Alois Jungbauer; Bernhard Sissolak
Journal:  Bioprocess Biosyst Eng       Date:  2022-08-02       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.